RT @PGtzsche1: I have published several reviews based exclusively on regulatory documents. They showed far more serious harms than publishe…
RT @PGtzsche1: I have published several reviews based exclusively on regulatory documents. They showed far more serious harms than publishe…
RT @PGtzsche1: I have published several reviews based exclusively on regulatory documents. They showed far more serious harms than publishe…
RT @PGtzsche1: I have published several reviews based exclusively on regulatory documents. They showed far more serious harms than publishe…
RT @PGtzsche1: I have published several reviews based exclusively on regulatory documents. They showed far more serious harms than publishe…
RT @lifebiomedguru: When "the science" reliably misleads, the loss of trust is justified.
RT @PGtzsche1: I have published several reviews based exclusively on regulatory documents. They showed far more serious harms than publishe…
RT @PGtzsche1: I have published several reviews based exclusively on regulatory documents. They showed far more serious harms than publishe…
RT @PGtzsche1: I have published several reviews based exclusively on regulatory documents. They showed far more serious harms than publishe…
RT @PGtzsche1: I have published several reviews based exclusively on regulatory documents. They showed far more serious harms than publishe…
RT @PGtzsche1: I have published several reviews based exclusively on regulatory documents. They showed far more serious harms than publishe…
RT @PGtzsche1: I have published several reviews based exclusively on regulatory documents. They showed far more serious harms than publishe…
RT @lifebiomedguru: When "the science" reliably misleads, the loss of trust is justified.
RT @lifebiomedguru: When "the science" reliably misleads, the loss of trust is justified.
RT @lifebiomedguru: When "the science" reliably misleads, the loss of trust is justified.
@Frente_Amplio @MSPUruguay @Udelaruy @smuruguay He publicado varias revisiones basadas exclusivamente en documentos normativos. Mostraron daños mucho más graves que los informes de ensayos publicados, por ejemplo, de medicamentos para la depresión https://
RT @PGtzsche1: I have published several reviews based exclusively on regulatory documents. They showed far more serious harms than publishe…
RT @PGtzsche1: I have published several reviews based exclusively on regulatory documents. They showed far more serious harms than publishe…
RT @lifebiomedguru: When "the science" reliably misleads, the loss of trust is justified.
RT @lifebiomedguru: When "the science" reliably misleads, the loss of trust is justified.
When "the science" reliably misleads, the loss of trust is justified.
RT @PGtzsche1: I have published several reviews based exclusively on regulatory documents. They showed far more serious harms than publishe…
RT @PGtzsche1: I have published several reviews based exclusively on regulatory documents. They showed far more serious harms than publishe…
RT @PGtzsche1: I have published several reviews based exclusively on regulatory documents. They showed far more serious harms than publishe…
RT @PGtzsche1: I have published several reviews based exclusively on regulatory documents. They showed far more serious harms than publishe…
RT @PGtzsche1: I have published several reviews based exclusively on regulatory documents. They showed far more serious harms than publishe…
Je RT mais je n'ai pas encore lu l'article...
RT @PGtzsche1: I have published several reviews based exclusively on regulatory documents. They showed far more serious harms than publishe…
Bottled Smiles and HCV vax: trial reports vs regulatory documents.
RT @PGtzsche1: I have published several reviews based exclusively on regulatory documents. They showed far more serious harms than publishe…
RT @PGtzsche1: I have published several reviews based exclusively on regulatory documents. They showed far more serious harms than publishe…
RT @PGtzsche1: I have published several reviews based exclusively on regulatory documents. They showed far more serious harms than publishe…
RT @PGtzsche1: I have published several reviews based exclusively on regulatory documents. They showed far more serious harms than publishe…
RT @PGtzsche1: I have published several reviews based exclusively on regulatory documents. They showed far more serious harms than publishe…
Great review by Peter Gotzsche
RT @PGtzsche1: I have published several reviews based exclusively on regulatory documents. They showed far more serious harms than publishe…
RT @PGtzsche1: I have published several reviews based exclusively on regulatory documents. They showed far more serious harms than publishe…
RT @PGtzsche1: I have published several reviews based exclusively on regulatory documents. They showed far more serious harms than publishe…
🚨👇👇👇🚨 #OrganizedCrime
I have published several reviews based exclusively on regulatory documents. They showed far more serious harms than published trial reports, e.g. of depression drugs https://t.co/UfqPDPU3zd, https://t.co/qplDca6cj0, https://t.co/k4wotfZeFk and HPV vaccines
RT @theo_mazarakis: @RyanMarino You say that now but 1/958 middle aged women treated for urinary incontinence, showed "mild aggression" on…
@RyanMarino You say that now but 1/958 middle aged women treated for urinary incontinence, showed "mild aggression" on duloxetine. Just imagine if she had an AR-15 and a roof to piss on. https://t.co/FQfzYj7PBr
@GregEqEd @RyanMarino 1/ I checked the first two studies which you were to lazy to post a link to. I did not even touch the third since it clearly refers to violent suicide and not violence in general. Here are the first 2 studies: 1. https://t.co/FQfzYj7P
RT @keisuke4713: 欧州で腹圧性尿失禁治療 デュロキセチン(サインバルタ:SNRI)利点と害 メタ分析https://t.co/iYBzrd1oyP 腹圧性尿失禁のある中年女性の自殺と暴力のリスクを4〜5倍⬆️ 女性のコア精神的または潜在的な精神的イベントのリスク…
#メモ #薬害 #副作用
RT @keisuke4713: 欧州で腹圧性尿失禁治療 デュロキセチン(サインバルタ:SNRI)利点と害 メタ分析https://t.co/iYBzrd1oyP 腹圧性尿失禁のある中年女性の自殺と暴力のリスクを4〜5倍⬆️ 女性のコア精神的または潜在的な精神的イベントのリスク…
欧州で腹圧性尿失禁治療 デュロキセチン(サインバルタ:SNRI)利点と害 メタ分析https://t.co/iYBzrd1oyP 腹圧性尿失禁のある中年女性の自殺と暴力のリスクを4〜5倍⬆️ 女性のコア精神的または潜在的な精神的イベントのリスクを2倍⬆️ https://t.co/LO4FmhIR65 *結論に👆を含めず、関係考察は不可能と https://t.co/LrQgsc0I8m
RT @urologyhyderabd: In fact European Medicines Agency (EMA) releases information on the data submitted to it on request. The US and Canadi…
In fact European Medicines Agency (EMA) releases information on the data submitted to it on request. The US and Canadian Agencies keep it confidential. See a recent review on Duloxetine for SUI using that info and how it impacts conclusions. https://t.co/N
@CharlieSari @EquanimityNow_ @ChrisAikman2 They don‘t go into detail, but we know from clinical trials of antidepressants in non-depressed people that SSRI/SNRI can cause depression symptoms, anxiety and emotional disturbances. So confounding by indication
Considering benefits and harms of duloxetine for treatment of stress urinary incontinence: a meta-analysis of clin… https://t.co/X8PO5teFgO
Considering benefits and harms of duloxetine for treatment of stress urinary incontinence: a meta-analysis of clin… https://t.co/X8PO5teFgO
New NNT→Considering benefits and harms of duloxetine for treatment of stress urinary incontinence: a meta-analysis… https://t.co/7XXRUiGY3Q
Duloxétine dans l’incontinence urinaire : les risques seraient supérieurs aux bénéfices https://t.co/k4Zh6J0FMl
#Duloxetina mas daño que beneficio en #incontinencia de esfuerzo mujeres https://t.co/EGo37wLuyA
RT @RaulCalvoRico: Los efecs adversos d la duloxetina superan a los beneficios q ha demostrado en la incontinencia vesical https://t.co/Nkh…
RT @RaulCalvoRico: Los efecs adversos d la duloxetina superan a los beneficios q ha demostrado en la incontinencia vesical https://t.co/Nkh…
RT @RaulCalvoRico: Los efecs adversos d la duloxetina superan a los beneficios q ha demostrado en la incontinencia vesical https://t.co/Nkh…
Los efecs adversos d la duloxetina superan a los beneficios q ha demostrado en la incontinencia vesical https://t.co/NkhWyuP4ng
RT @RevistaMFSamfyc: Considerar los beneficios y perjuicios de la duloxetina para el tratamiento de la incontinencia urinaria de estrés htt…
RT @hhask: Benefits and harms of duloxetine for stress urinary incontinence: a meta-analysis of clinical study reports https://t.co/s4V425c…
Considerar los beneficios y perjuicios de la duloxetina para el tratamiento de la incontinencia urinaria de estrés https://t.co/lGAjr2pmqg
RT @MA_Gagnon: Cochrane Collaboration on Cymbalta:"when individual patient data were analyzed, the harms outweighed the benefits" https://t…
RT @MA_Gagnon: Cochrane Collaboration on Cymbalta:"when individual patient data were analyzed, the harms outweighed the benefits" https://t…
RT @MA_Gagnon: Cochrane Collaboration on Cymbalta:"when individual patient data were analyzed, the harms outweighed the benefits" https://t…
RT @MA_Gagnon: Cochrane Collaboration on Cymbalta:"when individual patient data were analyzed, the harms outweighed the benefits" https://t…
Cochrane Collaboration on Cymbalta:"when individual patient data were analyzed, the harms outweighed the benefits" https://t.co/FrryeXb4EI
RT @CMAJ: Stress urinary incontinence drug has substantial harms, marginal benefits https://t.co/2qjY6mI5jD #womenshealth #urology #patient…
RT @CMAJ: Stress urinary incontinence drug has substantial harms, marginal benefits https://t.co/2qjY6mI5jD #womenshealth #urology #patient…
RT @CMAJ: Stress urinary incontinence drug has substantial harms, marginal benefits https://t.co/2qjY6mI5jD #womenshealth #urology #patient…
Stress urinary incontinence drug has substantial harms, marginal benefits https://t.co/2qjY6mI5jD #womenshealth #urology #patientsafety https://t.co/jGS66aLWA5
RT @hhask: Benefits and harms of duloxetine for stress urinary incontinence: a meta-analysis of clinical study reports https://t.co/s4V425c…
RT @hhask: Benefits and harms of duloxetine for stress urinary incontinence: a meta-analysis of clinical study reports https://t.co/s4V425c…
RT @hhask: Benefits and harms of duloxetine for stress urinary incontinence: a meta-analysis of clinical study reports https://t.co/s4V425c…
Benefits and harms of duloxetine for stress urinary incontinence: a meta-analysis of clinical study reports https://t.co/s4V425cyR2 @CMAJ
RT @CMAJ: #StressUrinaryIncontinence drug linked to substantial harms, marginal benefit. https://t.co/ie1qhuf0NI #womenshealth #urology #pa…
#StressUrinaryIncontinence drug linked to substantial harms, marginal benefit. https://t.co/ie1qhuf0NI #womenshealth #urology #patientsafety https://t.co/hd7mLuhonr
RT @MiguelMolinaDH: Duloxetina en mujeres con incontencia urinaria de esfuerzo: balance riesgo/beneficio desfavorable https://t.co/ljPXJwd…
#Duloxetina dados su perfil de seguridad no aporta valor añadido a la #incontinencia urinaria en #mujeres https://t.co/kQ3a2bXYfO
Duloxetina en mujeres con incontencia urinaria de esfuerzo: balance riesgo/beneficio desfavorable https://t.co/ljPXJwdsj2
@uofcknes @CMAJ @OBrien_IPH Students taking #KNES493 in the winter17, here is the type of study we will review: risk out weighs the benefit https://t.co/7qGbbixil8
RT @rincondesisifo: (CMAJ) Duloxetina en la incontinencia de esfuerzo: los riesgos no justifican los beneficios https://t.co/Z3VtlBe3AW MA
#Stressurinaryincontinence drug duloxetine has substantial harms, marginal benefit: https://t.co/xbKeue84qo #womenshealth #urology https://t.co/X0AmmuW364
أضرار كبيرة لعقاقير #سلس_البول ،، https://t.co/YZBywWOUTl #جمعية_رفيدة #صحة_المرأة https://t.co/W2fHkwbBbt
RT @sanoysalvoblog: Duloxetina en mujeres con incontencia urinaria de esfuerzo: balance riesgo/beneficio desfavorable https://t.co/Rkt29Wg…
RT @sanoysalvoblog: Duloxetina en mujeres con incontencia urinaria de esfuerzo: balance riesgo/beneficio desfavorable https://t.co/Rkt29Wg…
Benefits & harms of duloxetine for stress urinary incontinence https://t.co/k1DWbbKqX6 *authors say don't use: leaves only surgery?*
RT @sanoysalvoblog: Duloxetina en mujeres con incontencia urinaria de esfuerzo: balance riesgo/beneficio desfavorable https://t.co/Rkt29Wg…
12 | Here's to hoping they do what Maund et al. show to be so critical to patient care https://t.co/uq9AhpSEsZ in @CMAJ
(CMAJ) Duloxetina en incontinencia urinaria de esfuerzo, balance beneficio/riesgo desfavorable (MA) https://t.co/YePjy9hPJJ
RT @sanoysalvoblog: Duloxetina en mujeres con incontencia urinaria de esfuerzo: balance riesgo/beneficio desfavorable https://t.co/Rkt29Wg…
RT @sanoysalvoblog: Duloxetina en mujeres con incontencia urinaria de esfuerzo: balance riesgo/beneficio desfavorable https://t.co/Rkt29Wg…
RT @sanoysalvoblog: Duloxetina en mujeres con incontencia urinaria de esfuerzo: balance riesgo/beneficio desfavorable https://t.co/Rkt29Wg…
RT @sanoysalvoblog: Duloxetina en mujeres con incontencia urinaria de esfuerzo: balance riesgo/beneficio desfavorable https://t.co/Rkt29Wg…
RT @sanoysalvoblog: Duloxetina en mujeres con incontencia urinaria de esfuerzo: balance riesgo/beneficio desfavorable https://t.co/Rkt29Wg…
RT @sanoysalvoblog: Duloxetina en mujeres con incontencia urinaria de esfuerzo: balance riesgo/beneficio desfavorable https://t.co/Rkt29Wg…
RT @sanoysalvoblog: Duloxetina en mujeres con incontencia urinaria de esfuerzo: balance riesgo/beneficio desfavorable https://t.co/Rkt29Wg…
RT @sanoysalvoblog: Duloxetina en mujeres con incontencia urinaria de esfuerzo: balance riesgo/beneficio desfavorable https://t.co/Rkt29Wg…